Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
Clinical trial NCT06202313 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06202313
- Sponsor
- Shengjing Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-10
- Primary completion
- 2025-12-30
- Enrollment
- 128
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.